Accession Number : ADA610972


Title :   Platform for Rapid Delivery of Biologics and Drugs to Ocular Cells and Tissues Following Combat Associated Trauma


Descriptive Note : Annual rept. 30 Aug 2012-29 Aug 2013


Corporate Author : TUFTS UNIV BOSTON MA


Personal Author(s) : Kumar-Singh, Rajendra ; Birke, Marco T


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a610972.pdf


Report Date : Sep 2013


Pagination or Media Count : 9


Abstract : The objective of this study is to develop a protein that can be injected directly into the eye while in the combat theater to prevent or reduce the damage to retinal cells following blast associated trauma. To this end, we propose use of a peptide (POD, peptide for ocular delivery) that we have previously shown to be capable of penetrating retinal cells in vivo. POD will be utilized to deliver melanoma inhibitor of apoptosis (ML-IAP) or X-linked inhibitor of apoptosis (XIAP) into retinal cells, neither of which have a cell penetrating capacity by themselves. We are using recombinant adenovirus as the gene expression system to synthesize the POD fusion proteins. At the end of Year 1 of this proposal, we have completed the construction of 1 (XIAP) of the recombinant adenovirus constructs and are at the penultimate step of generating the ML-IAP construct. Next steps are to purify these two proteins and evaluate their anti-apoptotic properties in vitro and ultimately in vivo. During the following year we will complete the construction of the ML-IAP construct and relevant controls and perform studies to test the anti-apoptotic properties of these recombinant proteins.


Descriptors :   *CELLS(BIOLOGY) , *DRUGS , *EYE , *TRAUMA , ADENOVIRUSES , CAPACITY(QUANTITY) , CONSTRUCTION , CONTROL , DAMAGE , DELIVERY , GENES , IN VIVO ANALYSIS , INHIBITORS , NEOPLASMS , PEPTIDES , PROTEINS , RETINA , THEATER LEVEL OPERATIONS , TISSUES(BIOLOGY) , WARFARE


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE